Nektar Therapeutics (NKTR) Misses Q4 EPS by 2c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $67.10 -1.84%
Revenue Growth %: -11.4%
Financial Fact:
Interest expense: -5.61M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -11.4%
Financial Fact:
Interest expense: -5.61M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.22), $0.02 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $23.9 million versus the consensus estimate of $21.69 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Redburn upgrades Southwest, stays bullish on Delta and United
- UBS cuts KOSPI target by nearly 10% to reflect higher rates
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
